Lymphocyte-specific protein 1 (LSP1) (LSP1)

Lymphocyte-specific protein 1 (LSP1) is an intracellular F-actin binding protein and a major phosphoprotein found in lymphocytes, neutrophils, macrophages, and endothelial cells [1][2]. It functions as a critical regulator of the actin cytoskeleton, facilitating leukocyte transendothelial migration and chemotaxis by modulating actin filament bundling and dynamics [2][3]. LSP1 is phosphorylated by several kinases, including MAPKAPK2 (MK2) and protein kinase C (PKC), which regulates its association with the cytoskeleton [1][4]. In clinical research, LSP1 is prominently recognized as a breast cancer susceptibility locus, with specific single nucleotide polymorphisms (SNPs) in the LSP1 gene significantly associated with an increased risk of the disease [5][6]. Additionally, altered expression of LSP1 is observed in various hematological malignancies, such as chronic myeloid leukemia and certain lymphomas, where it may serve as a diagnostic or prognostic marker [4][7]. While there are currently no FDA-approved drugs specifically targeting LSP1, it is an active area of research for developing therapies to treat inflammatory disorders and prevent cancer metastasis by inhibiting aberrant cell motility [3][8].

Other names

WP34pp52S37Leucocyte-specific protein 1Lymphocyte-specific antigen WP34

Modulation of actin cytoskeleton dynamics to inhibit or enhance cell motility and migration.